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Abstract
Background: At the onset, differentiation between abnormal non-epileptic movements, and epileptic seizures
presenting in early life is difficult as is clinical diagnosis and prognostic evaluation of the various seizure disorders
presenting at this age. Seizures starting in the first year of life including the neonatal period might have a favorable
course, such as in infants presenting with benign familial neonatal epilepsy, febrile seizures simplex or acute
symptomatic seizures. However, in some cases, the onset of seizures at birth or in the first months of life have a
dramatic evolution with severe cerebral impairment. Seizure disorders starting in early life include the “epileptic
encephalopathies”, a group of conditions characterized by drug resistant seizures, delayed developmental skills, and
intellective disability. This group of disorders includes early infantile epileptic encephalopathy also known as
Ohtahara syndrome, early myoclonic encephalopathy, epilepsy of infancy with migrating focal seizures, infantile
spasms syndrome (also known as West syndrome), severe myoclonic epilepsy in infancy (also known as Dravet
syndrome) and, myoclonic encephalopathies in non-progressive disorder.
Here we report on seizures manifesting in the first year of life including the neonatal period. Conditions with a
benign course, and those with severe evolution are presented. At this early age, clinical identification of seizures,
distinction of each of these disorders, type of treatment and prognosis is particularly challenging.
The aim of this report is to present the clinical manifestations of each of these disorders and provide an updated
review of the conditions associated with seizures in the first year of life.
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Background
Seizures are not uncommon clinical manifestations in
childhood and a frequent reason for consultation in
child neurology. In infancy, movements during epileptic
seizures are often subtle, unnoticed by parents and, not
easily recognized. Seizures are caused by abnormal and
excessive discharges of neurons, usually self-limited, and
often accompanied by abnormal behavior, and sensory-
motor manifestations [1]. The term epilepsy defines the
recurrences of two or more unprovoked seizures [2].
Seizure types have been recently classified according to
their site of onset in focal, generalized and unknown.
The focal seizures are further distinguished in: aware or
with impaired awareness, with motor or non-motor on-
set, and focal to bilateral tonic-clonic; the generalized, in
motor tonic-clonic, other motor and non-motor
(Absence); the unknown in motor tonic-clonic, other
motor and non-motor, and unclassified. [3, 4]. Various
etiological events cause seizures in childhood, the most
common being fever, infections, head injury, metabolic
dysregulation, noxious perinatal events (e.g., stroke), and
hypoxic-ischemic-encephalopathies [5]. Less frequent
causes of seizures in childhood include chromosomal
deletions, and duplications, cerebral malformations by
selected single gene mutations and inborn errors of
metabolism [2]. The prenatal and early life periods are
critical for brain development with rapid involving syn-
aptogenesis, dendritic arborization, myelination, apop-
tosis, and priming of excess process, and synapses, all
factors which concur for the normal cerebral growth [6].
Any pathologic events during this early period of life
might result in severe cerebral impairment with develop-
mental delay and intellectual disability, often associated
with epileptic seizures and various comorbidities [7, 8].
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Seizures occurring in the first year of life might have an
evolution ranging from benign to severe [9, 10]. Typic-
ally benign cases of seizures occurring in the first year of
life include Benign Familial Neonatal Epilepsy (BFNE),
Febrile Seizures simplex (FSs) and Acute Symptomatic
Seizures (ASS). Febrile Seizure complex (FSc) might
have a variable prognosis not always predictable. Severe
seizures presenting at an early age include the epileptic
encephalopathies a group of disorders defined on the
basis of “the notion that epileptic activity may contribute
to severe neurocognitive and behavioral dysfunction
above and beyond what would be expected from the
underlying pathology alone”. These impairments may
have a progressive course over time [11, 12]. Clinical
identification of the seizures by the parents and care-
givers is challenging, as are diagnosis and prognostic
counseling by the pediatricians and specialists in this
field. This report aims to present the clinical manifest-
ation of each of these disorders and provide an updated
review of the conditions associated with seizures in the
first year of life.
Early life seizure with usually benign course
Benign familial neonatal epilepsy
Unlike most cases of neonatal seizures, which have a
high frequency of disability, the neonatal prognosis is
usually benign in families affected by Benign Familial
Neonatal Epilepsy (BFNE) [10, 13]. The clinical features
of this disorder are relatively typical: the seizures begin
in the first days of life in otherwise healthy looking ba-
bies and are typically associated with a family history of
neonatal seizures. The affected infants tend to have a
normal course in the developmental stages and the sei-
zures tend to gradually disappear within the first months
of life. [13–15]. The condition is inherited as an auto-
somal dominant trait with both genders being affected,
and has been associated with a mutation in the KCN
gene, localized on chromosome 20q13.33 [16]. With the
term “KCNQ2 related epilepsy” are designed clinical
conditions encompassing the classical type of BFNE, the
Benign Familial Neonatal Infantile Seizures (BFNIS) and
the Benign Familial Infantile Seizures (BFIS) [17, 18].
KCNQ2 related disorders are also reported in patients
with epileptic encephalopathies [19]. Recently,
disorders caused by BFNE have also been reported in
individuals with KCNQ3 gene mutations [20]. A large
family has been followed for three generations by
some of the authors of the present article. In this
family, not all of the members showed the classic
evolution of the disorder: in one the seizures started
at the age of 3 months, another member showed fe-
brile seizures complex with EEG anomalies, and one
suffered from focal seizures lasting until the age of
10 years [21].
Acute symptomatic seizures
Seizures might be provoked by factors with onset in close
temporal relationship with a well-documented brain in-
sult. These events are referred to Acute Symptomatic
Seizures (ASS) [22], as Situation-Related-Seizures (SRS) or
also named as occasional, or reactive, or provoked sei-
zures. The 1989 classification of the ILAE includes these
events in the category of situation-related seizures because
they show an identifiable proximate cause and do not typ-
ically recur spontaneously [23]. Aside from the febrile sei-
zures and the infections directly involving the central
nervous system, the seizures might manifest following
trauma, intoxication, or anomalous administration of
drugs. Other factors inducing ASS include electrolytic
dysregulation, acute hypoglycemia, hypocalcemia, and
hyponatremia. The occurrence of the ASS is particularly
high in the infantile period since, at this age the brain
seems to be more susceptible to such insults. The seizures
present most frequently as motor tonic-clonic generalized
types. Focal or unilateral types are uncommon. Recently,
children with manifestations of transient generalized sei-
zures have been reported in association with wild gastro-
enteritis [24]. A new pathogenetic pathway, the so-called
“gut-brain axis”, has been reported as a causative event of
seizures. Falsaperla et al. [25] have reported a 10-month-
old male infant with seizures secondary to cow’s milk
protein allergy. Neurologic signs disappeared after the
suspension of the cow’s milk protein.
Febrile seizures simplex
Febrile Seizures (FS) are the most common convulsive
manifestations in childhood, affecting 4–6% of the
pediatric population [26]. FS are classified as simplex or
complex [27].
FSs are defined as a short (< 15 min.) generalized sei-
zures, not recurring within 24 h which occur during a
febrile illness not resulting from an acute disease of the
nervous system, in a child aged between 6 months and
5 years, with no neurologic deficits and no previous
afebrile seizures [27, 28]. Differential diagnosis is made
with viral meningitis in the presence of positive neurologic
signs, persisting loss of consciousness, and post-ictal
drowsiness. In one/third of cases and until the age of
5 years, the seizures tend to reappear with other episodes
of fevers. The evolution in epileptic seizures is rare, and al-
most similar to that of the general population, and no per-
sistent residual signs of motor, behavioral, and cognitive
disturbances are reported. In FSs, EEG recordings and
brain MRI are not necessary, while the lumbar puncture is
advised to be performed in FSs children less than 1-year-
old and those under antibiotic treatment. Intravenous,
intramuscular, buccal, intranasal or rectal benzodiazepines
are administered to stop the crises [28–30]. Prophylactic
pharmacologic treatment is not advised [28].
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Early life seizure with prognosis not predictable
Febrile seizures complex
Children with Febrile Seizures complex (FSc) have charac-
teristic clinical features opposite to those reported in FSs.
The principal features of the manifestations are focal, or
generalized, and prolonged seizures lasting more than
15 min, recurrence can happen within 24 h in the course
of the same febrile episode, the temperature might not be
elevated. Moreover the crises might be associated with
post-ictal neurologic abnormalities, most frequently post-
ictal palsy, or manifest in subjects with previous neuro-
logic deficits [28, 29]. FSc might manifest in different
ways, with onset before the first year of life or after 5 years,
it might be present in alternation with afebrile seizures, or
in members of a family affected by Genetic Epilepsy with
Febrile Seizures plus (GEFS+). Febrile status epilepticus
might also be recorded [27–29]. Patients with brain dam-
age are more affected than those without. Differential
diagnosis is posed with cerebral abscesses, meningo-
encephalitis, cerebral vascular malformations, cortical
thrombophlebitis, and autoimmune encephalitis. Diagnos-
tic investigations should include routinary analysis, an
EEG recording, lumbar puncture, and plasma electrolytes.
Brain MRI might also be indicated in patients with focal
seizures, and those with episodes that happened after
5 years of age. Brain MRI is advised in an emergency in
patients who present focal post-ictal deficit and persisting
loss of consciousness, and also in patients with immuno-
deficiency, or with seizures of particular long durations.
The acute treatment is based on the use of benzodiaze-
pines [30]. In FSc, prophylactic treatment might be useful
in reducing the frequency and the duration of the crises
but is not considered able to prevent the onset of subse-
quent epileptic seizures [29]. Very prolonged FSc is
thought to be associated with mesial temporal sclerosis
and temporal lobe epilepsy, but the direct relationship
among these disorders and FSc remains uncertain [31, 32].
FSc might affect child members of a family affected by
(GEFS+), a complex autosomal dominant disorder in
which individuals present with genetic mutations of
SCN2A (a voltage-gated sodium channel), or less fre-
quently of SCN1B [33, 34]. With this mutation, individuals
suffering from FSc might belong to a family in whom other
members are affected by a variety of seizure types, such as
myoclonic, tonic, and tonic-clonic seizures. One/third of
the GEFS+ patients are reported to have febrile seizures,
which manifest with crises of prolonged durations, present-
ing in children less than 2 years old and, with residual signs
including post-ictal hemiplegia [33].
Early life seizures with usually severe course
Neonatal seizures
Neonatal seizures have a fairly high incidence, usually
more than in any other period of life. In most cases the
neonatal seizures are due to acute dysfunction of the
cerebral nervous system and the most common cause is
hypoxic-ischemic encephalopathies [35], followed by
intracranial hemorrhage, infections and strokes. The in-
cidence rate of neonatal seizures is 1–2% of life births
[36, 37]. Neonatal seizures are distinguished according
to the presentation as clinical seizures, electroclinical
seizures and electroencephalographic seizures and based
on the pathophysiology in epileptic and non-epileptic
seizures [14]. EEG is particularly useful for diagnostic
evaluation (Fig. 1).
Neonatal epilepsy syndromes are uncommon, and rep-
resent a sizable subgroup of neonatal seizure etiologies
[38]. In this subgroup a genetic, metabolic, or structural
cause might be identified, whereas in some cases the
etiologic event cannot be determined using the current
diagnostic investigation. The genetic causes of neonatal
epilepsy are distinguished in: malformations of cortical de-
velopment; genetic-metabolic; genetic vascular; genetic
syndromic and genetic-cellular [38]. Neonatal seizures are
also included in the cohort of neurodegenerative disor-
ders, and in association with malformative cerebral syn-
dromes. A study on a prospective cohort of newborns
with seizures was conducted by Shellhaas et al. [39] on
611 patients enrolled in the Neonatal Seizure Registry US.
The study includes neonates with seizures related to epi-
leptic encephalopathies (without structural brain abnor-
malities), brain malformations, and benign familial
epilepsies. Among the group enrolled, 79 (13%) had epi-
lepsy, (35 epileptic encephalopathy, 32 congenital brain
malformation, 11 benign familial neonatal epilepsy and 1
benign neonatal seizures). In this study, KCN2 variants
were the most common genetic anomaly reported
within the group of patients with epileptic
encephalopathies.
The neonatal seizures may recognized an Inborn Error
of Metabolism (IEM), as a putative cause. Among these
the Pyridoxine-dependent epilepsy, the pyridox (am)ine
5′-phosphate oxidase (PNPO) deficiency, GLUT-1 (glucose
transporter 1) deficiency, non-ketotic hyperglycinemia,
maple syrup urine disease are the most quoted examples
[40]. Pyridoxine-dependent epilepsy (PDE) is an autosomal
recessive enzyme defect in the vitamin B6 metabolism. In
this disorder biochemical and genetic studies are available
for a correct diagnosis including elevated urinary alpha-
aminoadipic semialdehyde excretion and ALDH gene mu-
tation. Treatment consists of the use of pyridoxine, which
has been also proposed as an initial diagnostic approach in
cases of infantile refractory epilepsy of unknown cause
[41]. Pyridox (am)ine 5′-phospate oxidase (PNPO) defi-
ciency is due to the enzyme defect which converts pyridox-
ine 5′-phosphate and pyridoxamine 5′- phosphate (PLP)
into pyridoxal 5′-phosphate (PLP). Treatment with
pyridox-5′ phosphate in the first days of life has shown
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good therapeutic response [42, 43]. GLUT 1 (glucose
transporter 1) deficiency presents with respiratory distress,
hypotonia, absence of neonatal reflexes and less frequently
with arthrogryposis or joint laxity. Diagnosis is related to a
mildly elevated cerebrospinal fluid (CSF) glycine levels, and
normal or slightly elevated serum or plasma glycine levels.
Survey of variants in SLC6A gene might be diagnostic [44].
Non ketotic hyperglycinemia (NKH) is caused by a defi-
ciency in the glycine cleavage system presenting with
severe hypotonia and crisis of apnea [45]. The diagnosis is
based on the elevated glycine concentrations in CSF, in as-
sociation with an increased CSF/plasma glycine ratio [46].
Maple syrup urine disease (MSUD) is caused by deficit of
branched-chain alfa ketoacid dehydrogenase complex. Mu-
tations in the BGKDHA, BCKDHB, and DBTI genes have
been associated with this disorder [47].
Except for PDE, PLP and PNPO no treatment is
known for the above mentioned IEM conditions.
Regardless of the etiology of the neonatal seizures, prog-
nosis in most of the cases is severe. In fact the brain is
more susceptible in the neonatal period and in infancy
than in older children and this vulnerability is linked to a
more express activity age-dependent of receptors for exci-
tatory rather than inhibitory neurotransmission [48]. For a
long time, neonatal seizures were treated with phenobar-
bital and phenytoin as the first-line drugs. Recently,
phenobarbital and phenytoin treatment in neonatal sei-
zures has been questioned because of doubtful seizure
control and for the consequence of long term alterations
in brain structures [49, 50]. As demonstrated in rat CAT
neurons, treatment with phenobarbital disrupts GABergic
synaptic maturation [51]. Pharmacokinetic data for new
drugs in treatment of neonatal seizures is limited. Treat-
ment with levetiracetam has been proposed to be effective
in a recent study [52].
Epileptic encephalopathies
Epileptic encephalopathies include severe epileptic disor-
ders that share similar characteristics: onset in early life,
persistent electroencephalographic abnormalities, drug-
resistant seizures of various types, and cognitive involve-
ment. The definition also includes the condition that
seizure activity per se, above and beyond the effects of
underlying causal factors, interferes with the develop-
mental skills of the affected children [4, 11, 12]. There is
agreement that uncontrolled seizures might provoke a
negative effect on the cerebral functions in the affected
patients. This is confirmed by the observation that chil-
dren unresponsive to treatment have a progressive de-
cline along the course of the disorder. At the same time,
it is well-known that children with West syndrome show
a better prognosis when seizures have an early diagnosis
and receive a precocious treatment [53, 54]. The same
results have been reported in drug-resistant epileptic
children submitted to surgical treatment, with the dem-
onstration of progressive improvement of the cognitive
function after the intervention [55, 56]. Certainly, the
persistence of the epileptic seizures and unresponsive-
ness to the treatment is consistent with the worsening of
the cognitive decline in the affected children, but the
underlying etiologic factors are of notable importance in
contributing to the deleterious brain effect. Epileptic
Fig. 1 Four day old boy affected by stroke with neonatal seizures onset. The picture shows the focal discharges located on the right hemisphere
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encephalopathies are predominantly symptomatic and
sporadic, and new technologies have identified several
genes involved in the etiology of these disorders [57].
The epileptic encephalopathy manifesting in the first
months of life include Early Infantile Epileptic Encephal-
opathy (EIEE) (also known as Ohtahara syndrome), Early
Myoclonic Encephalopathy (EME), Epilepsy of Infancy
with Migrating Focal Seizures (EIMFS), Infantile Spams
Syndrome (ISS) (also known as West syndrome), Severe
Myoclonic Epilepsy in infancy or Dravet Syndrome (DS),
and Myoclonic Encephalopathies in non-progressive dis-
order [5, 11, 12, 53, 54].
Early infantile epileptic encephalopathy - early myoclonic
encephalopathy
Early Infantile Epileptic Encephalopathy was first re-
ported by Ohtahara et al. in 1976 [58] and subsequently
overviewed in 16 patients by Yamatogy and Ohtahara in
2002 [59]. The syndrome is clinically characterized by
early onset seizures presenting in 30% of cases within
the first 10 days of life, by tonic spasms as seizure types
(either generalized and symmetrical or lateralized), and
with less frequency by focal and myoclonic seizures. The
intercritical EEG findings show high voltage bursts of
slow waves mixed with multifocal spikes, with phases of
flat suppression [59–61] (Fig. 2). Mutations in several
genes have been implicated, including ARX, STXBP1,
KCNQ2, SLC25A22, and CDKL5 [62–65]. Structural
cerebral anomalies are often detected by brain MRI,
including cerebral asymmetry, hemimegalencephaly,
lissencephaly and focal-cortical dysplasia [61, 65, 66].
Hypotonia, severe developmental delay, and respiratory
problems are associated with these seizure types. The
prognosis is poor, with severe intellective delay, and re-
sistance to drug treatment and to ketogenic diet. Transi-
tion to West syndrome is frequently observed.
The diagnostic criteria for Early Myoclonic Encephal-
opathy include early onset, and myoclonus as the main
seizure type with frequent episodes of erratic partial
seizures. Massive myoclonus, or tonic spasms have also
been reported. The EEG shows a pattern of burst-
suppression. Metabolic disorders are often recognized as
a causative event of the disorder as well as brain malfor-
mations [67]. Mutation in SLC25A22, which encodes the
mitochondrial glutamate/H+ symporter, has been associ-
ated with this encephalopathy [68]. Prognosis is poor.
EIEE and EME share many common characteristics and
the distinction between these epileptic disorders is ques-
tionable [69]. Covanis [70] claims that EME, contrarily
to EIEE, might manifest with different characteristics:
the tonic seizures are less frequent, the focal seizures
(when present) tend to appear later, the myoclonic sei-
zures are early onset, erratic, and frequently massives,
and the EEG suppression is longer and the paroxysm
shorter. The etiology is mainly of metabolic origin and
less structural. Also, the transition of EME in West syn-
drome is not frequently reported.
Epilepsy of infancy with migrating focal seizures
The Epilepsy of Infancy with Migrating Focal Seizures
(EIMFS) is also referred to as Malignant Migrating
Partial Seizures in Infancy (MMPSI) [71, 72]. In most of
the cases, EIMFS onset is reported in the firsts 6 months
of life, with almost continuous migrating polymorphous
focal seizures involving part of the body with hemi-
lateralization and electrographic multifocal discharges.
Fig. 2 One month old female with Ohtahara syndrome: The EEG recording shows the typical burst-suppression pattern
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The prognosis is poor, with evolution to the other types
of epileptic encephalopathies, such as Ohtahara syn-
drome and West syndrome. McTague et al. [73] reported
the clinical features of 100 children affected by MMPSI.
Among these children, focal motor seizures were re-
ported at onset in 64%; focal seizures affecting alternat-
ing sides of the body in 59%; secondary generalization in
17%; and epileptic spasms in 7%. Moreover, autonomic
features were also present in 43% and generalized tonic-
clonic seizures in 8% of the cases. Hypotonia and reduc-
tion of the occipitofrontal circumference (OFC) and
severe microcephaly was registered in most of the pa-
tients. Treatment with a high level of phenytoin gave
fairly good results. Among the 14 patients reported by a
National surveillance study in association with British
Pediatric Neurology Surveillance Unit, at presentation,
10 infants had focal motor seizures mainly involving the
face, eyes, and limbs with head-turning; the seizures
were generalized in five, generalized tonic in three and
clonic in two. An autonomic feature associated with sei-
zures was reported in 12 out 14 cases. EEGs showed
various patterns, ranging from subtle burst-suppression
with rhythm decrement to hypsarrhythmia, according to
the age of infant submitted to the EEG. In this group of
patients, genetic analysis identified two patients with
mutations in the newly discovered KCNT1 gene [73]. A
study was conducted on 12 patients, and data from a
further 34 collected from the literature by Howell et al.
[74] with the aim of better defining the clinical aspect of
early epileptic encephalopathies with SCN2A gene muta-
tions. In the group of 12 patients, multifocal interictal
epileptiform discharges were reported in all. At the onset
of symptoms, seven patients showed EIMFS clinical
expression and two of Ohtahara syndrome. The same
authors [74] report in five patients, an improved seizure
control with sodium channel blockers using high dosage
of phenytoin. The authors [74] concluded that SCN2A
encephalopathy is a frequent cause of EIMFS which
might manifest with three clinical phenotypes: neonatal-
infantile-onset groups (either with severe or intermediate
outcomes) and childhood-onset. SCN2A is recognized
by these authors as the second most common cause of
EIMFS. Pharmacological treatment attempts have been
carried out with several, known anticonvulsant drugs
including vigabatrin, stiripentol, valproic acid and cloba-
zam, but with poor results [74].
Infantile spasms syndrome
West syndrome is defined by the classic triad of infantile
spasms, hypsarrhythmia, and developmental arrest or re-
gression. West syndrome is also indicated as “infantile
spasms” and “epileptic spasms” because the spasms are
the most notable event. However, recently this disorder
has been indicated with the term “infantile spasms
syndrome” (ISS). In fact, this term includes the onset of
seizures largely prevailing in infancy, the seizure types,
and the EEG findings as present features. As these fea-
tures tend to occur together, and at the same time the
application of the term “syndrome” seems to be correct
[3, 75–77]. West syndrome, according to the new no-
menclature, is considered a subtype of ISS since not all
of the triad is always present at the same time. ISS is the
most common among the group of epileptic encephalop-
athies. The estimated incidence of ISS is 2–3.5 per
10,000 live births [78]. In the typical manifestation, the
seizures appear within the first year of life, usually be-
tween 4 and 6 months, with episodes of axial spasms of
short duration occurring in clusters and at awakening.
Psychomotor delay might precede, follow or coincide
with the spasms. In rare occasions, the spasms might
not manifest clearly and might express with less obvious
signs, which are referred to as “subtle spasms”. The
intercritical EEG presents with a high voltage arrhythmia
and asynchronous, slow, and sharp waves, in a chaotic
distribution with multifocal spikes and poly-spikes. Crit-
ical EEG might show a pattern of synchronous and sym-
metric spike- wave discharges (Fig. 3). Atypical modified
hypsarrhythmia might be observed at the intercritical
EEG with a pattern of asymmetric features, focal dis-
charges, and semi-periodic burst- suppression [75].
Prognosis in most of the cases is severe, both for the
control of seizures and for intellective delay. The under-
lying causes of ISS are numerous. Symptomatic causes
are the most common, being identified in about 60–70%
of cases. Among these, the most frequent are the outcomes
of hypoxic-ischemic encephalopathy and perinatal strokes,
neurocutaneous syndromes including Sturge-Weber syn-
drome, and Tuberous Sclerosis Complex, structural brain
disorders, malformative syndromes, inborn errors of me-
tabolism and as recently shown immunologic factors. Gene
mutations have been recognized as a causative event of
ISS. The first reports of gene mutation in ISS were linked
to the Aristeless (ARX1) and the cyclin-depend Kinase-like
(CDKL5) [79]. Genes frequently involved with ISS are the
PAFAH1B1/LIS1, DCX, and TUBA1A855. Other genes
implicated in the etiology of ISS are DKL5, STXBP1,
KCNQ2, GRIN2A, MAG12, SPTAN, FOXG1, NSD1,
WDR4 and RARS2 [60, 80–83]. There are multiple
treatment options for ISS, which can be used together or
individually under different situations. Hormonal, pharma-
cologic, ketogenic diet, and surgery are the eventual
options for treatment. Adrenocorticotrophic hormone
(ACTH) is widely used, with a wide range of dosage, but
the most carried out is 2–3 IU/Kg/day. ACTH treatment is
usually conducted for 3–4 weeks. Pharmacologic treatment
is linked to the use of vigabatrin (50–125 mg/kg/day) alone
or in association with other drugs. A ketogenic diet
(ATKINS) is recommended by several authors, firstly by
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Kossofl, who report good results in more than 45% of the
children treated with this diet [84]. Surgery is rarely used
and restricted to cases of documented focal epileptogenesis
and when pharmacologic treatment did not help [85].
Severe myoclonic epilepsy in infancy- Dravet syndrome
Since the initial description in 1978 [86] and subsequent
reports of Dravet, the clinical features of this disorder
are represented by severe myoclonic epilepsy with onset
in infancy (SMEI), associated with multiple seizure types,
last-during epileptic seizures with frequent episodes of
status epilepticus, often triggered by fever [87, 88]. The
incidence is reported as about 1 in 40,000 infants
[89, 90]. In its classical clinical feature, patients affected
by this disorder initially growth normally, and seizures
begin around the age of 6–8 months trigger by fever, and
presenting with either low and high temperature. Seizures
are last –during and might have generalized or unilateral
expression. Less commonly, seizures might also develop
without fever. The EEG might be initially normal or
present with diffuse or unilateral slowing after the epi-
sodes of prolonged course. There are five principal diag-
nostic criteria for classical DS: normal developmental
before seizure onset; two or more febrile seizures complex
before the age of 12 months; myoclonic, hemiclonic or
generalized tonic-clonic seizures; two last-during seizures;
and refractory seizures after the age of 2-years [88]. How-
ever, in patients with SMEI related to SCN1A gene muta-
tions, some of the above-mentioned clinical signs might
be absent, including the different age of onset, type of
seizures, EEG pattern, and the non-involvement of
intellective capacity [91–94]. For DS linked to SCN1A
mutation, the term SCN1A-related epilepsy syndrome has
been proposed. This syndrome might also show a wide
clinical expression involving not only the brain but also
cardiac, hearing, vision, movement issues, urinary, bowel,
and endocrine functions [95]. Psychiatric disturbances and
autistic behavioral have frequently been reported [95]. The
EEG typically shows focal or multifocal spike-waves, sharp
waves, and slow waves and spikes activity [88]. In approxi-
mately 70–80% of cases, DS is related to a genetic dis-
order, mostly carrying a de novo SCN1A mutation, and
including truncating, missense, and splice- site mutations
in 40%, 40%, and 20% of cases, respectively [96]. Other
genes have been associated with DS-like phenotypes, in-
cluding SCN2A, SCN8A, SCN9A, SCN1B, PCDH19,
GABRA1, GABRAG2, STXBP1, HCN1, CHD2, and
KCNA2 [95–100]. SCN1A mutations cause an inhibition
of the GABAergic inhibitory interneurons, leading to ex-
cessive neuronal excitation. This model is referred to as
the interneuron hypothesis and is the most accepted mech-
anism for DS [96–98]. The SCN1A genes encode nine
mammalian voltage-gated sodium channel alfa subunits,
and their mutation is one of the most common causes of
epilepsy detected in 70% to 85% of patients with DS and
3% to 6% of patients with generalized epilepsy with febrile
seizures plus (GEFS+) [91, 97–100]. SCN1A haploinsuffi-
ciency producing Nav1.1 dysfunction mainly affects
GABAergic neurons, which according to the affected site,
cortex, cerebellum, basal ganglia, or hypothalamus, are the
cause of epileptic seizure, ataxia, crouching gait, thermal
dysregulation, and sleep disturbances [96, 98, 101, 102].
Fig. 3 Six months female with ISS. The critical EEG shows the presence of synchronous and symmetric spike- wave discharges
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The prognosis for DS is severe for both epileptic seizures
and cognitive impairment, and the mortality rate is signifi-
cant and half of the deaths are recorded as Sudden Unex-
pected Death (SUDEP) [103]. DS treatment is based on the
use of appropriate drugs. Sodium channel blocking drugs
are not advised in cases of DS due to the genetic defects af-
fecting the sodium channels. In most cases, the drugs used
in the treatment of DS produce little benefit. Pharmaco-
logical treatment attempts have been carried out with
oxcarbamazepine, phenytoin, bromides, topiramate, leveti-
racetam, vigabatrin, stiripentol (STP), valproic acid,
clobazam. [73] The effectiveness of STP was tested in 32
patients affected by DS, 15 of which had SCN1A mutations.
The authors found that STP treatment was able to reduce
the frequency of seizures in 72 ± 23% of the mutation
group, compared to 50 ± 40% of the non-mutation group
[104]. Triple treatment with valproate, topiramate, and STP
has been effective in DS case report [105]. In a study of
Myers et al. [106] performed on 41 patients with DS, treat-
ment with STP displayed a long-term reduction of about
50% of cases both in patients with generalized than those
with focal epileptic seizures. In general STP treatment in
DS is effective and well-tolerated and markedly reduce the
frequency of prolonged seizures [107]. New drugs have
been proposed for the treatment of SD [108].
Myoclonic encephalopathies in nonprogressive disorder
The syndrome, also termed as “Myoclonic Status in
Nonprogressive Encephalopathies (MSNE)” begins in
early age, with an average age of 10 months [109, 110].
Three subgroups are recognized with a different pres-
entation concerning the etiology, clinical aspect, EEG,
and the evolution. In the first group, the etiology is gen-
etic; the seizures are myoclonic or myoclonic absence-
types. The EEG features consist of periodic theta-delta
activity predominant in the central regions or might ap-
pear as brief runs of slow delta rhythm in the posterior
regions. In the second group, the etiology is unknown
with bilateral positive myoclonic jerks or relevant abnor-
mal movements; the EEG shows diffuse slow back-
ground with status epilepticus or theta-delta rhythm
prevalent in frontal regions. In the third group, the de-
velopmental delay is mild, and focal motor seizures in-
volve mainly the face; the EEG displays generalized
spike-wave paroxysms [111].
Conclusions
The diagnosis of early-life seizures is complex, and in-
cludes conditions that can have a favorable course or
dramatic effects. The onset of the first episode is cause
of great concern for the parents and caregivers, and
there is pressure for the pediatrician to express an im-
mediate diagnosis. Correct diagnosis can help to pro-
duce appropriate treatment and accurate prognosis. The
first problem is to differentiate epileptic seizures from
abnormal non-epileptic movements. Video-registration
from the parents might help with this distinction.
Early onset seizures are a clinical expression of various
disorders with different etiologies and prognosis. The
benign type of early-life seizures is associated with a nor-
mal physical and neurological examination, adequate de-
velopmental milestones, good eye contact, and prompt
response to the archaic reflexes. In this regard, the
absence of cerebral impairment is often a positive prog-
nostic sign.
Epileptic seizures are usually accompanied by others
abnormal clinical manifestations. A clinical examination
might indicate the presence of anomalies on the skin,
face, and body organs, indicating a neurocutaneous, a
malformative syndrome, an inborn errors of metabolism
or other neurologic disorders.
It is also relevant to note the frequency and complex-
ity of seizure types which might be indicative of the
severity of the disorders. Video-EEG registration are of
notable importance as are the ophthalmologic examin-
ation and brain MRI. Recently, genetic analyses are re-
vealing the gene mutations involved and will likely make
relevant contributions to assignments of a correct diag-
nosis. In the group of epileptic encephalopathies, the
electroclinical definition and diagnosis of each of the
various disorders particularly in the precocious phases is
relevant but not simple, because of the similarity of pres-
entation and characteristic of seizures of the affected in-
fants to shift from one type to another. Moreover, the
electroclinical patterns reported in these patients might
be influenced by several factors such as the causative
event, the age of seizure onset, the time of EEG record-
ing and the treatment already performed leading to in-
conclusive results on the type of epileptic disorders. All
of the seizures belonging to the group of EE show resist-
ance to pharmacological drugs, to hormonal treatments,
and to ketogenic diet. Prognosis in EE patients is usually
severe and mainly based on the causative event. Correct
diagnosis, appropriate and precocious treatment, are the
best way to improve the course of the disorders.
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